We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+25.15%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$8.17B
AUM Growth
+$2.55B
Cap. Flow
+$12.3M
Cap. Flow %
0.15%
Top 10 Hldgs %
61.52%
Holding
432
New
171
Increased
73
Reduced
69
Closed
99

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.5M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$36.1M
3
SNY icon
Sanofi
SNY
+$34.1M
4
CYTK icon
Cytokinetics
CYTK
+$31.4M
5
WAT icon
Waters Corp
WAT
+$25.6M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$147M
2
PTCT icon
PTC Therapeutics
PTCT
+$72.4M
3
IMVT icon
Immunovant
IMVT
+$55.7M
4
DDOG icon
Datadog
DDOG
+$31.8M
5
AVNS
Avanos Medical
AVNS
+$28M

Sector Composition

Rank Sector Weight
1 Miscellaneous 55.89%
2 Healthcare 30.09%
3 Technology 6.58%
4 Consumer Discretionary 3.42%
5 Communication Services 1.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLGN icon
351
CollPlant Biotechnologies
CLGN
$6.71M
– –
-6,400
Closed -$34.3K
CLMT icon
352
Calumet Specialty Products
CLMT
$4.67B
– –
-7,335
Closed -$263K
CRBP icon
353
Corbus Pharmaceuticals
CRBP
$214M
– –
-364,000
Closed -$3.42M
CYTK icon
354
PUT
Cytokinetics
CYTK
$10.1B
– –
-200,000
Closed -$13.2M
DBI icon
355
Designer Brands
DBI
$267M
– –
-12,082
Closed -$68.7K
DDS icon
356
Dillards
DDS
$10.3B
– –
-427
Closed -$244K
DVA icon
357
DaVita
DVA
$11.7B
– –
-42,978
Closed -$6.61M
ENR icon
358
Energizer
ENR
$1.45B
– –
-1,200,000
Closed -$19.7M
ESPR
359
DELISTED
Esperion Therapeutics
ESPR
– –
-3,930,125
Closed -$10.8M
EVGN icon
360
Evogene
EVGN
$8.5M
– –
-456,587
Closed -$352K
F icon
361
Ford
F
$58.3B
– –
-19,253
Closed -$222K
FFBC icon
362
First Financial Bancorp
FFBC
$3.46B
– –
-9,000
Closed -$251K
FIVN icon
363
CALL
FIVE9
FIVN
$2.49B
– –
-1,250,000
Closed -$19M
FIX icon
364
Comfort Systems
FIX
$56.7B
– –
-2,356
Closed -$3.25M
FSLY icon
365
Fastly Inc
FSLY
$3.28B
– –
-12,432
Closed -$361K
GEHC icon
366
GE HealthCare
GEHC
$31.1B
– –
-118,289
Closed -$8.42M
GOVX icon
367
GeoVax Labs
GOVX
$2.52M
– –
-269,253
Closed -$372K
GTX icon
368
Garrett Motion
GTX
$5.22B
– –
-10,146
Closed -$184K
H icon
369
Hyatt Hotels
H
$15.6B
– –
-17,175
Closed -$2.47M
ICCM icon
370
IceCure Medical
ICCM
$7.64M
– –
-90,400
Closed -$816K
ICLR icon
371
Icon
ICLR
$12.7B
– –
-60,268
Closed -$6.67M
QTEX
372
QTREX Quantum
QTEX
$55.9M
– –
-4,139,086
Closed -$1.85M
IPGP icon
373
IPG Photonics
IPGP
$3.32B
– –
-1,835
Closed -$210K
IQV icon
374
IQVIA
IQV
$44.1B
– –
-60,884
Closed -$10.4M
IRM icon
375
Iron Mountain
IRM
$34.8B
– –
-2,351
Closed -$240K
13 14
15
16 17

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Armistice Capital held 432 positions worth $8.17B, up 45% from $5.62B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Armistice Capital's Q2 2026 filing shows 171 new, 73 increased, 69 reduced and 99 closed positions. Its largest new stake was Waters Corp: 75,004 shares worth $28.1M. The largest sale was Travere Therapeutics, an estimated $147M.

By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, up from 46% a quarter earlier, followed by Healthcare and Technology.

  • Armistice Capital's largest Q2 2026 buy was Waters Corp: 75,004 shares worth $28.1M.
  • Armistice Capital added most to Regeneron Pharmaceuticals in Q2 2026, an estimated $36.5M increase.
  • Armistice Capital's biggest Q2 2026 reduction was Travere Therapeutics, cutting an estimated $147M.
  • Armistice Capital fully exited Avanos Medical in Q2 2026, selling an estimated $28M.
  • Armistice Capital's ten largest holdings make up 62% of its $8.17B portfolio in Q2 2026.
  • Armistice Capital opened 171 new positions and closed 99 in Q2 2026.
  • Armistice Capital's portfolio value rose 45% quarter-over-quarter to $8.17B.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.